BR9916972B1 - composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção. - Google Patents

composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção.

Info

Publication number
BR9916972B1
BR9916972B1 BRPI9916972-0A BR9916972A BR9916972B1 BR 9916972 B1 BR9916972 B1 BR 9916972B1 BR 9916972 A BR9916972 A BR 9916972A BR 9916972 B1 BR9916972 B1 BR 9916972B1
Authority
BR
Brazil
Prior art keywords
well
pharmaceutical compositions
production process
delayed release
release pharmaceutical
Prior art date
Application number
BRPI9916972-0A
Other languages
English (en)
Other versions
BR9916972A (pt
Inventor
Gerald Huber
Peter Gruber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to BRPI9916972-0A priority Critical patent/BR9916972B1/pt
Publication of BR9916972A publication Critical patent/BR9916972A/pt
Publication of BR9916972B1 publication Critical patent/BR9916972B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI9916972-0A 1999-01-29 1999-01-29 composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção. BR9916972B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI9916972-0A BR9916972B1 (pt) 1999-01-29 1999-01-29 composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI9916972-0A BR9916972B1 (pt) 1999-01-29 1999-01-29 composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção.
PCT/IB1999/000180 WO2000044353A1 (de) 1999-01-29 1999-01-29 Pharmazeutische zusammensetzungen

Publications (2)

Publication Number Publication Date
BR9916972A BR9916972A (pt) 2001-11-06
BR9916972B1 true BR9916972B1 (pt) 2010-05-18

Family

ID=11004817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9916972-0A BR9916972B1 (pt) 1999-01-29 1999-01-29 composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção.

Country Status (15)

Country Link
US (1) US6962717B1 (pt)
EP (1) EP1146862B1 (pt)
JP (1) JP2002535353A (pt)
AT (1) ATE238040T1 (pt)
AU (1) AU764469B2 (pt)
BR (1) BR9916972B1 (pt)
CA (1) CA2360655C (pt)
DE (1) DE59905248D1 (pt)
DK (1) DK1146862T3 (pt)
ES (1) ES2197600T3 (pt)
MX (1) MXPA01007463A (pt)
NO (1) NO329231B1 (pt)
NZ (1) NZ513037A (pt)
PT (1) PT1146862E (pt)
WO (1) WO2000044353A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
PT1190712E (pt) * 2000-09-22 2005-01-31 Smb Technology Composicao de esferas de tramadol para administracao oral uma vez por dia
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1279402B1 (en) * 2001-07-26 2006-11-29 Ethypharm Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules
AU2011205217B2 (en) * 2001-08-06 2013-06-13 Euro-Celtique S.A. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
WO2003057195A1 (en) * 2002-01-11 2003-07-17 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
WO2004093883A2 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
BRPI0415242B8 (pt) * 2003-10-10 2021-05-25 Ethypharm Sa microgrânulos de liberação gradual contendo extrato de gingko biloba e o processo para fabricar estes
EP1680110B1 (en) * 2003-11-04 2011-01-05 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US7662802B2 (en) * 2004-09-17 2010-02-16 Gluconova, LLC Halide-free glucosamine-acidic drug complexes
ES2546258T3 (es) 2005-03-22 2015-09-22 Stada Arzneimittel Ag Ibuprofeno solubilizado
GR1006875B (el) * 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
PL1915137T3 (pl) * 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
BRPI0715835A2 (pt) * 2006-08-24 2013-07-23 Boehringer Ingelheim Pharma processo para preparar comprimidos de dicloridrato de pramipexol
MX2009002235A (es) 2006-08-30 2009-03-13 Jagotec Ag Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina.
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
EP3354276B1 (en) 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
WO2010001413A2 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN102686111A (zh) 2009-10-14 2012-09-19 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP2340812A1 (en) * 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
WO2012142413A2 (en) * 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof
US20140328884A1 (en) * 2011-12-16 2014-11-06 Celanese Eva Performance Polymers, Inc. Controlled release vehicles having desired void volume architectures
BR112014021433A2 (pt) * 2012-03-02 2017-07-18 Meda Pharma Gmbh & Co Kg formulações farmacêuticas
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
KR102472588B1 (ko) 2013-02-20 2022-12-01 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지 니트라이트의 약제학적 제형 및 이의 용도
US8652527B1 (en) * 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN104922078B (zh) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
US20190008787A1 (en) 2015-07-17 2019-01-10 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US20180185378A1 (en) * 2017-01-05 2018-07-05 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109715156A (zh) 2016-07-14 2019-05-03 尔察祯有限公司 用于治疗细菌感染的头孢布烯和克拉维酸的组合
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
DK58983D0 (da) 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
SE457505B (sv) 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
EP0212745B1 (en) 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
SE455836B (sv) 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
SE8803822D0 (sv) 1988-10-26 1988-10-26 Novel dosage form
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
SE9002017D0 (sv) 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
AU8050791A (en) 1990-06-20 1992-01-07 Advanced Polymer Systems Inc. Compositions and methods for the controlled release of soluble active substances
SE9002339L (sv) 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
GB9025372D0 (en) 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
AU1587392A (en) 1991-03-15 1992-10-21 Norwich Eaton Pharmaceuticals, Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
JPH07223970A (ja) 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
PT871434E (pt) 1995-12-21 2002-02-28 Ferring Farma Lab Composicao farmaceutica oral de libertacao modificada contendo 5-asa e processo para o tratamento de doencas do intestino
AU710109B2 (en) 1996-01-16 1999-09-16 Ap Pharma, Inc. Topical delivery of drugs to the lower gastrointestinal tract
JP2001503766A (ja) 1996-11-12 2001-03-21 フアーマシア・アンド・アツプジヨン・アー・ベー 複数の多孔質セルロースマトリクス（ｐｃｍ）を含むコンパクト部材、その製造および使用方法

Also Published As

Publication number Publication date
CA2360655A1 (en) 2000-08-03
WO2000044353A1 (de) 2000-08-03
EP1146862B1 (de) 2003-04-23
DK1146862T3 (da) 2003-07-21
JP2002535353A (ja) 2002-10-22
EP1146862A1 (de) 2001-10-24
AU1980899A (en) 2000-08-18
BR9916972A (pt) 2001-11-06
CA2360655C (en) 2007-03-20
NO20013336L (no) 2001-09-25
NZ513037A (en) 2003-05-30
DE59905248D1 (de) 2003-05-28
MXPA01007463A (es) 2002-06-04
NO20013336D0 (no) 2001-07-05
ATE238040T1 (de) 2003-05-15
ES2197600T3 (es) 2004-01-01
AU764469B2 (en) 2003-08-21
PT1146862E (pt) 2003-09-30
NO329231B1 (no) 2010-09-20
US6962717B1 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
BR9916972B1 (pt) composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção.
EP2277510A3 (en) Controlled release preparation
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
RU2009106681A (ru) Гранулированные фармацевтические композиции
AU4121297A (en) Galenic form with extended release of milnacipran
ES2153498T3 (es) Proceso para preparar formas de dosificacion farmaceutica solidas.
DE60236850D1 (de) Tabletten, die in der mundhöhle schnell zerfallen
EP0296740A3 (en) Hyaluronic acid derivatives and their production
DE60118395D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen
FI2341905T4 (fi) Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
NO20000913L (no) Sfæriske mikropartikler inneholdende lineære polysakkarider
CA2478811A1 (en) Tasted masked veterinary solid compositions
FI79942C (fi) Pao polykaprolakton baserat inert bindemedel foer oralt administrerbara laekemedel och foerfarande foer framstaellning av en galenisk form innehaollande detta bindemedel.
ATE223955T1 (de) Traubenkerne, kaltgepresstes traubenkernöl, traubenkernschrot und traubenkernmehl
DK616186A (da) Farmaceutisk praeparat med retarderet frigivelse af ibuprofen
PT1077687E (pt) Forma farmaceutica em particulas multiplas com libertacao programada e pulsada e processo para a sua preparacao
GEP20094589B (en) Orally dispersible pharmaceutical composition and process for the preparation thereof
ATE234608T1 (de) Mikrokapseln mit verzögerter freisetzung von wirkstoffen
US7575926B1 (en) Method of identification of compounds effective against suppressed cancer cells
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер
WO2005034919A3 (en) Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
EA200401145A1 (ru) Оральная фармацевтическая композиция с модифицированным высвобождением
EP1724265A4 (en) ANTICANCER AGENT
RU99106460A (ru) Порошковая смесь

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: DISPHAR INTERNATIONAL B.V. (NL), DISPHAR R&D B.V. (NL)

B25A Requested transfer of rights approved

Free format text: DISPHAR INTERNATIONAL B.V. (NL)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 14A, 15A, 16A, 17A, 18A, 19A, 20A E 21A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.